Disclosures: Janet Johnston: Nothing to Disclose, Youssef Barbour: Nothing to Disclose, Lisa Townshend-Bulson: Gilead Sciences: Grant/Research Support, Kena Desai: Nothing to Disclose, Chriss Homan: Nothing to Disclose, Wileina Rhodes: Nothing to Disclose, Brian McMahon: Nothing to Disclose 749 QUANTITATIVE ANALYSIS AND INTEGRATION OF MACHINE LEARNING FOR BIOMARKER ASSESSMENTS AND THEIR ASSOCIATION WITH TREATMENT RESPONSE: INSIGHTS FROM THE ENLIVEN PHASE 2B TRIAL OF PEGOZAFERMIN Oliver Mansbach 1 Arun Sanyal 2 Rada Savic 3 Leo Tseng 1 Kemal Balic 1 Shibao Feng 1 Lillian Tsai 1 Mildred Gottwald 1 Maya Margalit 1 Germaine Agollah 1 Hank Mansbach 1 Quentin Anstee 4 , 1 89bio, 2 Virginia Commonwealth University, 3 UCSF School of Pharmacy, 4 Newcastle University, UK Background: Pegozafermin (PGZ) is a long-acting glycoPEGylated analog of fibroblast growth factor 21 (FGF21)
Medical evaluation is appropriate if symptoms: Are severe, persistent, or worsening Are accompanied by vomiting or dehydration Cause significant abdominal pain Interfere with nutrition or daily function Do not improve despite diet and portion adjustments Occur with new or concerning gastrointestinal symptoms Bottom line sulfur burps and bloating on GLP-1 medications Sulfur burps and bloating on GLP-1 medications are common digestive side effects driven by delayed gastric emptying , not abnormal digestion
In diabetic rats, a single injection of semaglutide-loaded hydrogel maintained therapeutic levels for 42 days, and pharmacokinetic modeling suggests quarterly dosing may be feasible in humans [138, 139]
This means your heart is pumping and contracting with more force and more strength
